ArticleDiscover oncology2025
Identification of stemness subtypes and prognostic modeling in thyroid cancer: the critical role of DPYSL3 in tumor progression and immune microenvironment.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeThe objective of this study was to develop and evaluate a novel classifier and prognostic model based on the stemness characteristics of thyroid cancer patients.
methodsUtilizing transcriptomic data from thyroid carcinoma (THCA) patients in The Cancer Genome Atlas (TCGA) database, we calculated the stemness index (mRNAsi) using the one-class logistic regression (OCLR) method. Patients were subsequently classified into three distinct subtypes through consensus cluster analysis.
resultsSubtype III, characterized by its stem-like properties, exhibited significantly lower overall survival (OS) and a higher somatic mutational burden. Comprehensive analysis of the tumor immune microenvironment (TIME) in Subtype III suggested an immunosuppressive phenotype. Through the application of four machine learning algorithms and LASSO regression, we identified key genes and constructed a prognostic model based on the stemness signature. This model revealed that patients in the high-risk group had lower progression-free survival (PFS) but may benefit more from immune checkpoint blockade therapy, as indicated by TIME analysis. Functional experiments demonstrated that the stemness signature gene DPYSL3 promotes the proliferation, migration, and invasion of thyroid cancer cells and is associated with cancer stem cell properties.
conclusionThis study provides a new strategy for thyroid cancer immunotherapy by integrating stemness-based classification and prognostic modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.